Bibliografía del artículo
1. Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am 34:1015-1030, 2005.
2. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 423:349-355, 2003.
3. Boyden LM, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521, 2002.
4. Gong Y, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523, 2001.
5. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19:179-192, 2013.
6. Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 8:727-738, 2005.
7. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8:739-750, 2005.
8. Hwang SY, Putney JW Jr. Calcium signaling in osteoclasts. Biochim Biophys Acta 1813:979-983, 2011.
9. Duncan RL, Akanbi KA, Farach-Carson MC. Calcium signals and calcium channels in osteoblastic cells. Semin Nephrol 18:178-190, 1998.
10. Dahl SG, et al. Incorporation and distribution of strontium in bone. Bone 28:446-453, 2001.
11. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 69:121-129, 2001.
12. Rybchyn MS, Slater M, Conigrave AD, Mason RS. An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts. J Biol Chem 286:23771-23779, 2011.
13. Barneo-Munoz M, et al. Lack of GDAP1 induces neuronal calcium and mitochondrial defects in a knockout mouse model of charcot-marie-tooth neuropathy. PLoS Genet 11:e1005115, 2015.
14. Ammann P, et al. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 19:2012-2020, 2004.
15. Buehler J, Chappuis P, Saffar JL, Tsouderos Y, Vignery A. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 29:176-179, 2001.
16. Barbara A, Delannoy P, Denis BG, Marie PJ. Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells. Metabolism 53:532-537, 2004.
17. Takahashi N, Sasaki T, Tsouderos Y, Suda T. S 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 18:1082-1087, 2003.
18. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18:517-523, 1996.
19. Li C, et al. Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment. J Bone Miner Res 25:968-975, 2010.
20. Marie PJ, Felsenberg D, Brandi ML. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int 22:1659-1667, 2011.
21. Tenti S, Cheleschi S, Guidelli GM, Galeazzi M, Fioravanti A. What about strontium ranelate in osteoarthritis? Doubts and securities. Mod Rheumatol 24:881-884, 2014.
22. Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 450:11-17, 2002.
23. Almeida MM, et al. Strontium ranelate increases osteoblast activity. Tissue Cell 48:183-188, 2016.
24. Aubin JE. Advances in the osteoblast lineage. Biochem Cell Biol 76:899-910, 1998.
25. Bellows CG, Heersche JN, Aubin JE. Inorganic phosphate added exogenously or released from beta-glycerophosphate initiates mineralization of osteoid nodules in vitro. Bone Miner 17:15-29, 1992.
26. Wang D, et al. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res 14:893-903, 1999.
27. Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res 7:683-692, 1992.
28. Hoemann CD, El-Gabalawy H, McKee MD. In vitro osteogenesis assays: influence of the primary cell source on alkaline phosphatase activity and mineralization. Pathol Biol (Paris) 57:318-323, 2009.
29. Seibel MJ. Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 32:83-113, vi-vii 2003.
30. Hauschka PV, Wians FH Jr. Osteocalcin-hydroxyapatite interaction in the extracellular organic matrix of bone. Anat Rec 224: 180-188, 1989.
31. Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990-1047, 1989.
32. Delmas PD. Biochemical markers of bone turnover for the clinical investigation of osteoporosis. Osteoporos Int 3(Suppl 1):81-86, 1993.
33. Bakker AD, Zandieh-Doulabi B, Klein-Nulend J. Strontium ranelate affects signaling from mechanically-stimulated osteocytes towards osteoclasts and osteoblasts. Bone 53:112-119, 2013.
34. Pilmane M, Salma-Ancane K, Loca D, Locs J, Berzina-Cimdina L. Strontium and strontium ranelate: Historical review of some of their functions. Mater Sci Eng C Mater Biol Appl 78:1222-1230, 2017.
35. Fromigue O, et al. Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate. J Cell Mol Med 13:2189-2199, 2009.
36. Takaoka S, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. The Calcium-sensing Receptor (CaR) is involved in strontium ranelate-induced osteoblast differentiation and mineralization. Horm Metab Res 42:627-631, 2010.
37. Atkins GJ, Welldon KJ, Halbout P, Findla DM. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20:653-664, 2009.
38. Fromigue O, Hay E, Barbara A, Marie PJ. Essential role of nuclear factor of activated T cells (NFAT)-mediated Wnt signaling in osteoblast differentiation induced by strontium ranelate. J Biol Chem 285:25251-25258, 2010.
39. Slater M, Patava J, Mason RS. Role of chondroitin sulfate glycosaminoglycans in mineralizing osteoblast-like cells: effects of hormonal manipulation. J Bone Miner Res 9:161-169, 1994.
40. Blair HC, Schlesinger PH, Huang CL, Zaidi M. Calcium signalling and calcium transport in bone disease. Subcell Biochem 45:539-562, 2007.
41. Fernandez JM, et al. Strontium ranelate prevents the deleterious action of advanced glycation endproducts on osteoblastic cells via calcium channel activation. Eur J Pharmacol 706:41-47, 2013.
42. Fernandez-Murga ML, Serna E, Sanz-Salvador L, Hervás-Lorente A, Portero J, Cano A. Respuesta de preosteoblastos a compuestos de estroncio o calcio: proliferación, diferenciación, mineralización y respuesta génica global. Osteoporos Metab Miner 5:133-140, 2013.